<SEC-DOCUMENT>0001193125-24-003957.txt : 20240108
<SEC-HEADER>0001193125-24-003957.hdr.sgml : 20240108
<ACCEPTANCE-DATETIME>20240108082225
ACCESSION NUMBER:		0001193125-24-003957
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240108
DATE AS OF CHANGE:		20240108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		24518474

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d653837ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>the Securities Exchange Act of 1934 (Amendment No. ) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant &#9744;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the Registrant &#9746; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check
the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ambrx Biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Johnson&nbsp;&amp; Johnson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and <FONT
STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2024, Johnson&nbsp;&amp; Johnson, a New Jersey corporation (the &#147;Company&#148;),
issued the following press release in connection with the Company&#146;s entry into a definitive agreement to acquire Ambrx Biopharma, Inc. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g653837g0107023932411.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media contacts:</B><BR>Brian Kenney<BR><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">215-620-0111</FONT></FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suzanne Frost</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">416-317-0304</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Investor contact:</B><B><BR></B>Raychel Kruper<BR><U>investor-relations@its.jnj.com<BR></U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Immediate Release </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson to Acquire Ambrx, Advancing
Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Portfolio of Clinical and Preclinical Programs, Including Lead Product
Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson&nbsp;&amp; Johnson&#146;s Commitment to Oncology Innovation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Novel Technology Platform Sets Stage for the Development of Next Generation ADCs and Targeted Oncologic Therapeutics </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEW BRUNSWICK, NJ (January 8, 2024) </B>&#150;&nbsp;Johnson&nbsp;&amp; Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to
acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an <FONT
STYLE="white-space:nowrap">all-cash</FONT> merger transaction for a total equity value of approximately $2.0&nbsp;billion, or $1.9&nbsp;billion net of estimated cash acquired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety of its candidate therapeutics in multiple
cancer indications, including ARX517, its proprietary ADC targeting PSMA for metastatic castration-resistant prostate cancer (mCRPC); ARX788, its proprietary ADC targeting human epidermal growth factor receptor 2&nbsp;(HER2) for metastatic HER2+
breast cancer; and ARX305, its proprietary ADC targeting <FONT STYLE="white-space:nowrap">CD-70</FONT> for renal cell carcinoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Ambrx&#146;s ADC
technology offers unique advantages in the conjugation of stable antibodies and cytotoxic linker payloads, which results in engineered ADCs that effectively kill cancer cells and limit toxicities,&#148; said Yusri Elsayed, M.D., M.H.Sc., Ph.D.,
Global Therapeutic Area Head, Oncology, Johnson&nbsp;&amp; Johnson Innovative Medicine. &#147;The results seen to date with ARX517 in mCRPC are promising and represent a potential first- and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> targeted therapy for the treatment of this aggressive disease. In addition, Ambrx&#146;s pipeline and ADC platform present exciting future opportunities to deliver enhanced, precision biologics
as we look to transform the treatment of cancer and improve patients&#146; lives.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The planned acquisition presents a distinct opportunity for
Johnson&nbsp;&amp; Johnson to design, develop and commercialize targeted oncology therapeutics. Ambrx&#146;s proprietary ADC technology incorporates the advantages of highly specific targeting monoclonal antibodies securely linked to a potent
chemotherapeutic payload to achieve targeted and efficient elimination of cancer cells without the prevalent side-effects typically associated with chemotherapy. Building on a legacy of innovation in oncology and in prostate cancer, J&amp;J
scientists intend to work with Ambrx researchers, accelerating the Phase 1/2 <FONT STYLE="white-space:nowrap">APEX-01</FONT> study (<U>NCT04662580</U>) of ARX517 in advanced prostate cancer, while progressing a pipeline of novel ADC product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;With a median overall survival of less than two years and novel hormonal therapies moving earlier in the disease, significant unmet
need remains in the treatment of mCRPC,&#148; said Margaret Yu, M.D., Prostate Cancer Disease Area Leader, Johnson&nbsp;&amp; Johnson Innovative Medicine. &#147;We see a unique opportunity to harness the potential of this innovative ADC platform,
and with our deep understanding of prostate cancer, deliver a targeted PSMA therapeutic for addressing the growing needs of the more than 185,000 patients living with metastatic castration-resistant disease today<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ambrx was spun out of The Scripps Research Institute in 2003. The company pioneered the expanded
genetic code technology platform for incorporation of synthetic amino acid (SAA) into proteins at any selected site using industry standard cell lines. SAAs allow engineered precision biologics with site-specific, homogenous and stable conjugation,
overcoming limitations of traditional conjugation technologies. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Decision Resources (DRG) 2023 Report </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Merger Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the transaction, which was approved by the Johnson&nbsp;&amp; Johnson Board of Directors, Johnson&nbsp;&amp; Johnson (the Company) will
acquire all of the outstanding shares of Ambrx&#146;s common stock for $28.00 per share in cash through a merger of Ambrx with a subsidiary of the Company. The closing of the transaction is expected to occur in the first half of 2024, subject to
receipt of Ambrx shareholder approval, as well as clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. The approximately $1.9&nbsp;billion estimated net value of the transaction is based on
Ambrx&#146;s estimated fully diluted shares outstanding, less estimated net cash at the time of closing. Following completion of the transaction, Ambrx&#146;s common stock will no longer be listed for trading on the NASDAQ Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting treatment as a business combination or asset acquisition will be determined on or before the expected close of the transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Johnson&nbsp;&amp; Johnson </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At<B>
Johnson&nbsp;&amp; Johnson,&nbsp;we believe health is everything. Our strength in healthcare innovation empowers us to build a&nbsp;world where complex diseases are prevented, treated, and cured,&nbsp;where treatments are smarter and less invasive,
and&nbsp;solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact
health for humanity. Learn more at <U>https://www.jnj.com/</U> or at <U>www.janssen.com/johnson-johnson-innovative-medicine</U>. Follow us at</B><I> </I><B><U>@</U><U>JNJInnovMed</U>. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautions Concerning Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This
press release contains &#147;forward-looking statements&#148; regarding the acquisition of Ambrx. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If
underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson&nbsp;&amp; Johnson or Ambrx. Risks and uncertainties include, but
are not limited to: the risk that the closing conditions for the acquisition will not be satisfied, including the risk that clearance under the Hart-Scott-Rodino Antitrust Improvements Act or other applicable antitrust laws will not be obtained;
uncertainty as to the percentage of Ambrx stockholders that will vote to approve the proposed transaction at the Ambrx shareholder meeting; the possibility that the transaction will not be completed in the expected timeframe or at all; potential
adverse effects to the businesses of Johnson&nbsp;&amp; Johnson or Ambrx during the pendency of the transaction, such as employee departures or distraction of management from business operations; the risk of stockholder litigation relating to the
transaction, including resulting expense or delay; the potential that the expected benefits and opportunities of the acquisition, if completed, may not be realized or may take longer to realize than expected; challenges inherent in product research
and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product
recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by
competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers
of health care services and products; and trends toward health care cost containment. In addition, there will be risks and uncertainties related to the ability of the Johnson&nbsp;&amp; Johnson family of companies to successfully integrate the
programs and employees/operations and clinical work of Ambrx. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Johnson&nbsp;&amp; Johnson and Ambrx can
be found in Johnson&nbsp;&amp; Johnson&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended January&nbsp;1, 2023, including in the sections captioned &#147;Cautionary Note Regarding Forward-Looking
Statements&#148; and &#147;Item 1A. Risk Factors,&#148; and in the company&#146;s most recently filed Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and the company&#146;s subsequent filings with the Securities and Exchange
Commission (the SEC), and under the caption &#147;Risk Factors&#148; in Ambrx&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on November&nbsp;13, 2023, and elsewhere in Ambrx&#146;s reports filed with
the SEC. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, https://Ambrx.com or on request from Johnson&nbsp;&amp; Johnson or Ambrx. Neither Johnson&nbsp;&amp; Johnson nor Ambrx undertakes to
update any forward-looking statement as a result of new information or future events or developments, except as required by law. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional
Information and Where to Find It </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release may be deemed to be solicitation material in respect of the proposed acquisition of Ambrx by
Johnson&nbsp;&amp; Johnson. In connection with the proposed transaction, Ambrx intends to file relevant materials with the <U>SEC</U>, including Ambrx&#146;s proxy statement in preliminary and definitive form. INVESTORS AND STOCKHOLDERS OF AMBRX ARE
URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING AMBRX&#146;S PROXY STATEMENT (WHEN THEY ARE AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders of Ambrx
are or will be able to obtain these documents (when they are available) free of charge from the SEC&#146;s website at www.sec.gov, or free of charge from Ambrx on Ambrx&#146;s website at https://ir.Ambrx.com. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Johnson&nbsp;&amp;
Johnson and Ambrx and their respective directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be &#147;participants&#148; in the solicitation of proxies from stockholders of Ambrx in connection
with the proposed transaction. Information about Johnson&nbsp;&amp; Johnson&#146;s directors is set forth in Johnson&nbsp;&amp; Johnson&#146;s Proxy Statement on Schedule 14A for its 2023 Annual Meeting of Shareholders, which was filed with the SEC
on March&nbsp;15, 2023; and information about Johnson&nbsp;&amp; Johnson&#146;s executive officers is set forth in Johnson&nbsp;&amp; Johnson&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
January&nbsp;1, 2023, which was filed with the SEC on February&nbsp;16, 2023. Information about Ambrx&#146;s directors and executive officers is set forth in Ambrx&#146;s Proxy Statement on Schedule 14A for its 2023 Annual General Meeting of
Shareholders, which was filed with the SEC on April&nbsp;28, 2023. To the extent holdings of Johnson&nbsp;&amp; Johnson&#146;s or Ambrx&#146;s securities by their respective directors or executive officers have changed since the amounts set forth in
such 2023 proxy statements, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Additional information concerning the interests of
Ambrx&#146;s participants in the solicitation, which may, in some cases, be different than those of Ambrx&#146;s stockholders generally, will be set forth in Ambrx&#146;s proxy statement relating to the proposed transaction when it becomes
available. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g653837g0107023932411.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g653837g0107023932411.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  2 , # 2(  A$! Q$!_\0
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M -0US;F-9O\ =SSS[@5Y?%#/'X'T'[0#LDU9FB#?W, ?ED-7:^./^1Q\'_\
M7V?_ $..HA6GK47]W\3>M@J*4,,];>TL_37Y[&O)XYTP7E[9PVVH7-U9N4DA
MM[<NQP2"1@]!CJ<=14]OXRT:XT%]86=UMHW\ME9/G#]EVCN<BL'P0!_PFGC
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=\:M'M5D! ^0]J**WG\,O\*."C_%I_P#7R7Z'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
